Experimental design for vaccine preparations against human malignant tumors.
The cancer cell is immunoresponsive and indirectly immunocompetent cell inserting itself in an extremely delicate system of natural antibodies and their respective anti-idiotypes. In regulatory sense it mimicks--in the Richter's model of immune system function--second order of response by antigenic cell surface product of malignant transformation, acting functionally as incomplete anti-idiotypic antibody (homobody) with exteriorized tumor antigen. It successfully competes with the natural anti-idiotypic antibodies replacing their repressive function by inducive one, and by doing so, changing natural antibody response by two orders of magnitude. The proposed experimental design would hybridize in separate experiments in one molecule: anti-HLA and anti-tumor xenogeneic antibodies obtained from animals and used for passive immunization; unaltered tumor antigen with organ-specific histocompatibility antigen having a preserved capacity of associative recognition. The latter process of humoral exteriorization of antigens would be elicited in animals and these immunoglobulin molecules (homobodies) would be used in humans for active immunization or in isogeneic animals for a production of antisera for passive immunization. Both these types of immunization would revert deranged immunological response in the cancer patient back to its normal order. Appropriate absorptions at critical steps would assure high specificity of the antisera.
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology / Q000302:isolation & purification; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control; D009374:Neoplasms, Experimental / Q000276:immunology; D014612:Vaccines
D000951:Antigens, Neoplasm; D006680:HLA Antigens; D007130:Immunoglobulin Idiotypes; D014612:Vaccines